EyePoint Pharmaceuticals, Inc. (EYPT)
| Market Cap | 269.31M |
| Revenue (ttm) | 34.44M |
| Net Income (ttm) | -45.39M |
| Shares Out | 28.74M |
| EPS (ttm) | -3.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $9.37 |
| Previous Close | $9.59 |
| Change ($) | -0.22 |
| Change (%) | -2.29% |
| Day's Open | 9.62 |
| Day's Range | 9.10 - 9.94 |
| Day's Volume | 266,547 |
| 52-Week Range | 3.51 - 15.06 |
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and E...
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...
WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...
WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration -
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...
WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help im...
WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...
- No unexpected safety findings during the course of the study -
WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...
EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q3 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...
EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, wi...
WATERTOWN, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...
- Q 3 20 20 net product revenues are estimated to be between $ 5.5 - $ 5.9 million, as healthcare facilities began reopening from COVID-19 closures -
WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...
WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...
EyePoint Pharmaceuticals (EYPT) news from yesterday concerning a massive deal has EYPT stock continuing to climb higher on Friday. The post EyePoint Pharmaceuticals News: Why EYPT Stock Is Soaring 21% T...
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...
EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q2 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) moved lower by 2.5% in pre-market trading after the company reported Q4 results.
- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic -
- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers - - Collaboration to bring DEXYCU to ImprimisRx’s established cu...
WATERTOWN, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...
WATERTOWN, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...
- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline -
Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.
If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.
EyePoint Still Has A Very Promising Future
- Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities -
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2019 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 25.00% and 12.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-treated eyes vs. 75.0% in sham eyes, a 40% reduction 36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-tre...
EyePoint's stock offering isn't sitting well with shareholders today. Here's why.
WATERTOWN, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic product...
– EYP-1901 combines vorolanib with EyePoint’s bioerodible Durasert™ technology as a six-month sustained release intravitreal therapeutic program to potentially reduce injection frequency of currently ...
As of late, it has definitely been a great time to be an investor in EyePoint.
About EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treat... [Read more...]
| Industry Biotechnology | IPO Date Jan 27, 2005 |
| Stock Exchange NASDAQ | Ticker Symbol EYPT |
Financial Performance
In 2020, EYPT's revenue was $34.44 million, an increase of 69.10% compared to the previous year's $20.37 million. Losses were -$45.39 million, -20.07% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is 19.25, which is an increase of 105.44% from the latest price.